Sorafenib for relapsed FLT3-ITD-positive acute myeloid leukemia postallogeneic stem cell transplantation presenting as leukemia cutis

被引:1
作者
Brodie, Rachel [1 ]
Langabeer, Stephen E. [2 ]
Quinn, John [3 ]
McMenamin, Mairin E. [4 ]
Hayden, Patrick J. [1 ]
机构
[1] St James Hosp, Dept Haematol, Dublin, Ireland
[2] St James Hosp, Canc Mol Diagnost, Dublin D08 RX0X, Ireland
[3] Beaumont Hosp, Dept Haematol, Dublin, Ireland
[4] St James Hosp, Dept Histopathol, Dublin, Ireland
来源
CLINICAL CASE REPORTS | 2019年 / 7卷 / 12期
关键词
acute myeloid leukemia; allogeneic stem cell transplantation; FLT3; mutation; leukemia cutis; relapse; sorafenib;
D O I
10.1002/ccr3.2487
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Relapse of FLT3-mutated acute myeloid leukemia (AML) following allogeneic stem cell transplantation is associated with poor survival. The clinical utility of sorafenib monotherapy in this setting is described in a patient presenting as leukemia cutis.
引用
收藏
页码:2579 / 2580
页数:2
相关论文
共 2 条
[1]   Inhibition of FLT3 in AML: a focus on sorafenib [J].
Antar, A. ;
Otrock, Z. K. ;
El-Cheikh, J. ;
Kharfan-Dabaja, M. A. ;
Battipaglia, G. ;
Mahfouz, R. ;
Mohty, M. ;
Bazarbachi, A. .
BONE MARROW TRANSPLANTATION, 2017, 52 (03) :344-351
[2]   Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation [J].
Lee, Sung Ho ;
Paietta, Elisabeth ;
Racevskis, Janis ;
Wiernik, Peter H. .
AMERICAN JOURNAL OF HEMATOLOGY, 2009, 84 (10) :701-702